Scarica l'app Stockscreener
6.49
2.81%
-0.15
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Astria Therapeutics Inc Borsa (ATXS) Ultime notizie
Astria Therapeutics Inc expected to post a loss of 48 cents a shareEarnings Preview - TradingView
Astria Therapeutics price target raised to $28 from $27 at Wedbush - TipRanks
Wedbush Adjusts Price Target on Astria Therapeutics to $28 From $27, Keeps Outperform Rating - Marketscreener.com
Astria Therapeutics (NASDAQ:ATXS) Given Buy Rating at HC Wainwright - Defense World
Astria Therapeutics Advances Clinical Trials and Financials - TipRanks
Astria Therapeutics: Promising Developments and Strategic Advancements Justify Buy Rating - TipRanks
Astria Therapeutics, Inc. SEC 10-K Report - TradingView
Astria Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update - BioSpace
Astria Therapeutics: Promising Pipeline and Strong Financials Drive Buy Rating - TipRanks
Astria Therapeutics posts marginally smaller-than-expected quarterly net loss per share - Marketscreener.com
Astria Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results - TradingView
Astria Therapeutics, Inc. (NASDAQ:ATXS) Shares Acquired by New York State Common Retirement Fund - Defense World
Brokerages Set Astria Therapeutics, Inc. (NASDAQ:ATXS) PT at $25.67 - Defense World
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Marketscreener.com
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Learn to Evaluate (ATXS) using the Charts - Stock Traders Daily
Astria Therapeutics’ (ATXS) “Buy” Rating Reiterated at HC Wainwright - Defense World
Astria Therapeutics (ATXS) Projected to Post Earnings on Monday - Defense World
HC Wainwright Reaffirms "Buy" Rating for Astria Therapeutics (NASDAQ:ATXS) - MarketBeat
Astria Therapeutics (ATXS) Expected to Announce Quarterly Earnings on Monday - MarketBeat
Press Release From Business Wire: Astria Therapeutics, Inc. - UrduPoint News
Astria Therapeutics Initiates ALPHA-ORBIT Phase 3 Pivotal Trial of Navenibart in Hereditary Angioedema - Business Wire
Can Astria's Navenibart Change the Game for HAE Patients? Phase 3 Trial Begins After 95% Attack Reduction - StockTitan
Can Astria Therapeutics' Conference Appearance Signal New Developments in Allergic Disease Treatments? - StockTitan
Astria Therapeutics to Present at Upcoming TD Cowen 45th Annual Health Care Conference - Business Wire
Calculating The Intrinsic Value Of Astria Therapeutics, Inc. (NASDAQ:ATXS) - Yahoo Finance
When the Price of (ATXS) Talks, People Listen - Stock Traders Daily
Astria Therapeutics to Present at Upcoming American Academy of Allergy, Asthma and Immunology and World Allergy Organization Joint Congress - Business Wire
Astria Therapeutics (NASDAQ:ATXS) Shares Pass Below Fifty Day Moving Average – What’s Next? - Defense World
Astria Therapeutics: A High-Conviction Bet On HAE - Seeking Alpha
Astria Therapeutics, Inc. (NASDAQ:ATXS) Receives $25.67 Consensus Price Target from Analysts - Defense World
How to Take Advantage of moves in (ATXS) - Stock Traders Daily
Astria Therapeutics, Inc. (NASDAQ:ATXS) Receives $25.67 Consensus Target Price from Brokerages - MarketBeat
Astria Therapeutics (NASDAQ:ATXS) Stock Rating Upgraded by Citizens Jmp - MarketBeat
Astria Therapeutics (NASDAQ:ATXS) Now Covered by Analysts at JMP Securities - MarketBeat
Angioedema Pipeline 2024: Therapies Under Investigation, - openPR
Astria Therapeutics to Present at Upcoming Oppenheimer 35th Annual Healthcare Life Sciences Conference - sharewise
Astria wins new Outperform rating at JMP on drug technology - MSN
Astria Therapeutics, Inc. (NASDAQ:ATXS) Short Interest Update - MarketBeat
Astria Therapeutics to Present at Upcoming Western Society of Allergy, Asthma & Immunology Annual Scientific Session - Business Wire
Breakthrough HAE Treatment Data: Navenibart Shows Rapid Quality of Life Improvements in Clinical Trial - StockTitan
JMP Securities starts Astria Therapeutics stock at Market Outperform - MSN
JMP Securities Initiates Coverage of Astria Therapeutics (ATXS) with Market Outperform Recommendation - MSN
Astria Therapeutics' Shares Rise After JMP Securities Initiates Coverage With Outperform Rating - Marketscreener.com
Astria stock wins new Outperform at JMP (ATXS:NASDAQ) - Seeking Alpha
JMP Securities starts Astria Therapeutics stock at Market Outperform By Investing.com - Investing.com Canada
JMP Securities Initiates Astria Therapeutics at Outperform -January 31, 2025 at 08:17 am EST - Marketscreener.com
JMP Securities starts Astria Therapeutics stock with $26 target By Investing.com - Investing.com Canada
JPMorgan Chase & Co. Increases Position in Astria Therapeutics, Inc. (NASDAQ:ATXS) - Defense World
0.37%
0.15%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):